Lokathi Therapeutics

Executive Summary

Lōkahi Therapeutics is a private biotechnology company headquartered in La Jolla, California, founded in 2020. The company is pioneering a novel approach it terms 'Actual Intelligence (ai²),' which integrates human clinical judgment with rigorous scientific evaluation to develop intelligent medicines. Its lead program, Apitox, is a non-narcotic therapy derived from purified honey bee venom, targeting inflammation and pain. With a focus on oncology and immunology, Lōkahi aims to address unmet medical needs in chronic pain and inflammatory conditions, leveraging the unique bioactive properties of bee venom peptides. The company operates in the competitive biotech landscape of Southern California and has not yet disclosed funding rounds or valuation.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for Apitox70% success
• Q3 2026Release of preclinical efficacy data for Apitox in pain models80% success
• Q1 2027Announcement of strategic partnership or licensing deal for Apitox50% success